About us
TetraKit Technologies (“TetraKit”) was founded in 2021 as a spin-out from the University of Copenhagen. The key innovations in our company originate from the Herth lab at the University of Copenhagen’s Institute of Chemistry, a global leader in utilizing tetrazine ligation click chemistry in radiopharmaceutical applications.
Business Model
At TetraKit Technologies, we develop innovative radiopharmaceuticals in-house and collaborate with partners to broaden their application across oncology.
In-house drug development
We acquire high-potential targeting molecules through in-licensing and develop them via the TetraKit Platform
Read more
Platform Partnership
We collaborate with partners and engage in co-development projects, offering best-in-class labelling of any class of biomolecule with astatine-211 and other radiohalogens
Read more
